Allo-SCT is used to exploit GVL effect in high-risk relapsed non-Hodgkin's lymphoma (NHL). Here, we retrospectively analyzed 34 high-risk NHL patients who underwent auto-SCT followed closely by reduced-intensity allo-SCT ('tandem auto-allo') from January 2002 to November 2010. The search for an allogeneic donor was started at the beginning of salvage regimen. Median patients' age was 47 (27-68) years; histotypes were: diffuse large B-cell n ¼ 5, follicular n ¼ 14, transformed follicular n ¼ 4, mantle-cell n ¼ 5, plasmocytoid lymphoma n ¼ 1, anaplastic large T-cell n ¼ 2, peripheral T-cell n ¼ 3. Donors were HLA-identical siblings (n ¼ 29) or 10/10-matched unrelated individuals (n ¼ 5). Median interval between auto-SCT and allo-SCT was 77 days . At a median follow-up of 46 (8-108) months since allo-SCT, 5-year OS is 77% (61-93) and PFS is 68% (51-85). Disease relapse or progression occurred in six patients, 100-day TRM was 0%, 2-year TRM incidence was 6%. In conclusion, tandem transplantation is feasible in high-risk NHL patients having a HLA-identical donor. This approach could represent a suitable therapeutic option for those patients with high-risk NHL potentially benefitting from further therapy after auto-SCT. Donor searches should be started promptly whenever such an approach is chosen. Keywords: non-Hodgkin's lymphoma; tandem; autologous; allogeneic; SCT INTRODUCTION High-dose therapy followed by auto-SCT is the standard of care for most relapsed non-Hodgkin's lymphoma (NHL) patients.
INTRODUCTION
High-dose therapy followed by auto-SCT is the standard of care for most relapsed non-Hodgkin's lymphoma (NHL) patients. 1, 2 Unfortunately, relapse after auto-SCT remains the most important cause of treatment failure. Allogeneic hematopoietic SCT (allo-SCT) yields lower relapse rates compared with auto-SCT because of its GVL effect [3] [4] [5] [6] but on the other hand, its feasibility could be limited by the TRM. 7, 8 Some risk factors have been associated with poor outcome after salvage therapy followed by auto-SCT, 1,2,9-11 underlying the need for improving prognosis of these patients. A tandem autologous-allogeneic transplantation approach could have the advantage of combining cytoreduction with GVL effect with the aim of ameliorating the outcome of those patients for whom high-dose chemotherapy followed by auto-SCT gives unsatisfactory results.
The aim of this retrospective study is to evaluate the feasibility and safety of tandem 'auto-allo' in poor prognosis NHL patients.
PATIENTS AND METHODS
We analyzed the outcome of 34 consecutive high-risk adult NHL patients who underwent auto-SCT followed closely by reduced-intensity allo-SCT from January 2002 to November 2010 at two Institutions (Institut PaoliCalmettes, Marseille, France; Istituto Humanitas, Milano, Italy). Tandem transplantation decision relied on the high-risk disease, needing some consolidation therapy after auto-SCT, and on the hypothesis of a high GVL effect when a significant cytoreduction occurred after auto-SCT. Poor prognosis factors defining high-risk disease were: chemorefractory disease, histology unlikely to be cured by auto-SCT alone (peripheral T-cell-, transformed follicular-and mantle-cell lymphoma), relapse after prior auto-SCT, relapse after at least one therapeutic line but without prior auto-SCT, unfavorable relapse either after first or second therapeutic line. Unfavorable relapse was defined as relapse within 1 year since the end of last treatment (including or not rituximab) and/or occurring at extranodal sites. The search for a HLA-identical allogeneic donor had been started at the beginning of salvage regimen. Preparative regimen for reduced-intensity allo-SCT was an association of fludarabine-BU-anti-thymocyte globulin 12, 13 or fludarabine-CY with or without thiotepa. 3 Auto-SCT conditioning was realized using BEAM regimen or high-dose Melphalan. GVHD prophylaxis included CY alone or in combination with MTX. Only HLA-identical sibling or 10/10-matched-unrelated donors using 4-digit HLA typing were allowed to perform allo-SCT. Patients and donors signed written informed consents on protocols approved by review boards of Institut Paoli-Calmettes (Marseille, France) and Istituto Humanitas (Milano, Italy).
Kaplan-Meier method was used to analyze the OS andPFS; 14 cumulative incidences of relapse/progression, TRM, acute and chronic GVHD were calculated using competing risk analysis. 15 Acute GVHD was graded according to current criteria. 16 Chronic GVHD severity was initially classified using Seattle criteria, 17 then a re-evaluation using National Institute of Health classification was performed. 18 Chimerism data were collected: analysis was performed at þ 30, þ 60, þ 90 and beyond, every 30-60 days until chimerism reached 495% donor. At Institut Paoli-Calmettes analysis was performed on peripheral blood CD3 þ population, whereas at Istituto Humanitas analysis was performed on whole peripheral blood. Classical prognostic factors were studied using Cox regression by the mean of univariate and multivariate analysis when appropriate. 19 Time-dependent Cox regression was used to look at any correlation between acute and chronic GVHD and OS, PFS, TRM and relapse or progression.
RESULTS
Main patients' and transplant's characteristics are shown in Table 1 Inserm, CBT-510, Marseille, France and same period fulfilled high-risk criteria but did not undergo tandem transplantation. Reasons for tandem transplantation were: chemorefractory disease (n ¼ 7), histology unlikely to be cured by auto-SCT alone (n ¼ 3 peripheral T-cell lymphoma, n ¼ 3 transformed follicular lymphoma, n ¼ 1 mantle-cell lymphoma), relapse after prior auto-SCT (n ¼ 4), relapse after at least one therapeutic line but without prior auto-SCT (n ¼ 9), unfavorable relapse either after first or second therapeutic line (n ¼ 7). Unfavorable relapses are detailed as follows: relapse within 1 year since the end of last treatment (n ¼ 3), relapse within 1 year since the end of last treatment including rituximab (n ¼ 1), relapse occurring within 1 year since the end of last treatment and under rituximab maintenance (n ¼ 1), relapse occurring at extranodal sites (n ¼ 2). Of note, the seven patients with histologies unlikely to be cured by auto-SCT alone did not fill any of the other mentioned criteria for tandem transplantation. Histologies of each risk group and conditioning regimens are detailed in Table 1 legend.
Allogeneic peripheral blood after mobilization was the source of stem cells in 33 patients, one case of BM donation occurred. Median interval between diagnosis and allo-SCT was 32 months (5-219). Median interval between auto-SCT and allo-SCT was 77 days (36-197). Median prior therapeutic lines before tandem transplantation were 2 (1-4). Three patients received tandem transplant upfront due to chemorefractory disease: in these cases the search for an allogeneic donor started when the disease was shown to be refractory. Overall, 16 patients were in CR, 13 were in PR and five had progressive disease (PD) at time of allo-SCT (Table 1) .
Successful engraftment of allogeneic stem cells occurred in all patients. Chimerism data were available for 30 patients (88%). All of these evaluable patients reached 495% donor chimerism at a median of 60 days after allo-SCT (range: 21-321). No significant differences in chimerism kinetics were observed among patients in CR, PR or PD before allo-SCT (P ¼ 0.14): a trend toward faster time to complete donor chimerism was found among patients in PR vs those in CR (median 38 vs 98 days, P ¼ 0.07). No donor lymphocyte infusion was performed for any patient.
At a median follow-up of 46 (8-108) months since allo-SCT, 5-year OS is 77% (61-93) and PFS is 68% (51-85) (Figure 1) . Disease relapse or progression occurred in six patients (cumulative incidence ¼ 22% at 2 years), 100-day TRM was 0%, 2-year estimate of cumulative incidence was 6% (Figure 2 ). Causes of TRM were: sepsis with subsequent multiorgan failure in two patients and severe extensive chronic GVHD in one patient. Ten patients developed grade X2 acute GVHD and fifteen patients chronic GVHD, with a cumulative incidence of 29% (14-44) and 45% (27-63), respectively. Median day (range) of occurrence was 33(14-56) and 123 (95-1688) for grade X2 acute and chronic GVHD, respectively. Two patients were not evaluable for chronic GVHD since they died before day þ 90 after allo-SCT. Among the 15 patients with chronic GVHD, 3 presented with limited form (mild according to National Institute of Health classification) and 12 with extensive one (four mild and eight moderate according to National Institute of Health classification). Notably, no severe chronic GVHD occurred so far among living patients. Median duration of systemic immunosuppressive treatment for chronic GVHD was 12 months (range: 3-105) from GVHD diagnosis. At last follow-up, two patients are still under immunosuppression, at þ 74 and þ 105 months from GVHD diagnosis.
Disease status before allo-SCT and number of prior therapeutic lines were the only significant factors in multivariate models for relapse or progression and PFS. Relapse/progression incidence was 12%, 15% and 60% among patients in CR, PR and PD at allo-SCT, respectively, (P ¼ 0.02). This translated into better PFS in CR vs PR vs PD patients (81%, 66% and 40%, P ¼ 0.11) and, to a lesser extent, OS (87%, 72% and 60%, P ¼ 0.37). Disease status, interval between auto-SCT and allo-SCT and hematopoietic cell transplantation-specific comorbidity index were significant in the univariate analysis for grade X2 acute GVHD. No significant predictive factors for OS, TRM or chronic GVHD were found.
It is worth noting that the interval between auto-SCT and allo-SCT, as well as conditioning regimens used (both for auto-SCT and allo-SCT), did not significantly influence the occurrence of acute or chronic GVHD and TRM. Abbreviations: ALCL ¼ anaplastic large T-cell lymphoma; ATG ¼ anti-thymocyte globulin; DLBCL ¼ diffuse large B-cell lymphoma; FL ¼ follicular lymphoma; MCL ¼ mantle-cell lymphoma; PD ¼ progressive disease; PL ¼ plamocytoid lymphoma; PTCL ¼ peripheral T-cell lymphoma. Detailed histologies among groups of risk factors were: n ¼ 7 chemorefractory disease (n ¼ 1 DLBCL, n ¼ 4 FL, n ¼ 1 MCL, n ¼ 1 PL), n ¼ 7 histology unlikely to be cured by auto-SCT alone (n ¼ 1 MCL, n ¼ 3 transformed FL, n ¼ 3 PTCL), n ¼ 4 relapse after prior auto-SCT (n ¼ 2 DLBCL, n ¼ 1 FL, n ¼ 1 transformed FL), n ¼ 9 relapse after at least one therapeutic line but without prior auto-SCT (n ¼ 5 FL, n ¼ 3 MCL, n ¼ 1 ALCL), n ¼ 7 unfavorable relapse either after first or second therapeutic line (n ¼ 2 DLBCL, n ¼ 4 FL, n ¼ 1 ALCL). Conditioning regimens for allo-SCT were: fludarabine 150 mg/m 2 total dose, oral BU 8 mg/kg or i.v. 6.4 mg/kg total dose, ATG Thymoglobuline 2.5 mg/kg total dose administered on day-3, n ¼ 17; fludarabine 150 mg/m 2 total dose, i.v. 6.4 mg/kg total dose, ATG Thymoglobuline 5 mg/kg total dose administered on days -2 and -1, n ¼ 8; fludarabine 90 mg/m 2 total dose, CY 900 mg/m 2 total dose, n ¼ 5; thiotepa 12 mg/kg total dose, fludarabine 60 mg/m 2 total dose, CY 60 mg/kg total dose, ATG Thymoglobuline 7 mg/kg total dose administered on days -4 and -3, n ¼ 2; thiotepa 12 mg/kg total dose, fludarabine 60 mg/m 2 total dose, CY 60 mg/kg total dose, n ¼ 1; BEAM, n ¼ 1.
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Grade 2-4 acute GVHD negatively impacted on NRM (P ¼ 0.02) and OS (P ¼ 0.001), while no correlation with relapse or progression was found (P ¼ 0.99). A trend toward impaired PFS among patients with grade 2-4 acute GVHD was observed (P ¼ 0.12).
When analyzing correlation between chronic GVHD and outcome, we observed that reduction of relapse/progression incidence among patients with chronic GVHD (1 event out of 15 chronic GVHD vs 3 out of 17 GVHD-free patients) was offset by increase of NRM (3/15 vs 0/17), thus resulting in similar OS and PFS among patients with or without chronic GVHD (P ¼ 0.48 and P ¼ 0.72, respectively).
Hazard ratio (95% confidence interval) for relapse/progression was 0.26 (0.03-2.35) for patients with chronic GVHD vs those without it (P ¼ 0.23).
DISCUSSION
Allo-SCT closely following auto-SCT appeared to be feasible and with acceptable toxicity in this consecutive series of 34 high-risk NHL patients. Here, the prompt and successful search of a HLAidentical donor allowed us to perform allo-SCT early after the completion of high-dose chemotherapy and auto-SCT, in the attempt of improving prognosis of this high-risk group by the exploitation of GVL effect after the cytoreduction operated by highdose chemotherapy. Toxicity observed was acceptable, with 0 and 6% of early and 2-year TRM respectively. These results compared favorably with previous reported experiences using fludarabine/ CY 20 and fludarabine/TBI [21] [22] [23] as conditioning regimens for allo-SCT. In the study by Gutman et al., 21 overall TRM was 43% and chronic GVHD were 69% and 61% for sibling and unrelated donors, respectively. In another study published by Buser et al., 22 TRM rate was 20% and acute and chronic GVHD occurred in all evaluable patients. Results we obtained may be at least in part explained by the use of ATG during conditioning regimen in 73% of patients, thus leading to lower incidence of GVHD and also by the relatively better patients' profile in terms of number of previous treatments (median therapeutic lines were 2 vs 3 and 5 in the above cited studies, respectively). However, we cannot exclude that advances in supportive care in transplant setting occurring in recent years have contributed to the improvement of global outcome, and this despite the relatively high median patient's age in our cohort (47 years old vs 32.5 and 33.5 in the study by Gutman et al. 21 and Carella et al., 20 respectively) and slightly longer interval from diagnosis to allo-SCT (median 32 months vs 2.1 years and 26.5 months in the study by Buser et al. and Carella et al., respectively) .
Disease status at allo-SCT was shown to be an independent predictive factor of both OS and PFS, with a 15-26% rate improvement from PD to PR to CR (see Results); in our series the cytoreduction operated by high-dose chemotherapy before auto-SCT allowed one patient in PD before auto-SCT to convert to PR and two patients in PR to obtain CR before allo-SCT. We acknowledge that the evaluation of the specific contribution of auto-SCT is rather difficult, as only a low rate of improvement was observed (3 out of 20 patients with measurable disease at auto-SCT) and distinct conditioning regimens for allo-SCT were used, non-myeloablative and reduced-intensity (see Table 1 legend). In addition, only 12 patients (35%) had relapsed disease after prior auto-SCT at the moment of inclusion in the tandem salvage program, therefore any comparison with studies using allo-SCT only would be complicated.
Recently, a single center analysis on 27 patients with follicular lymphoma 24 found 96% OS and PFS using a similar tandem autoallo approach. Allo-SCT after reduced-intensity conditioning with fludarabine/CY was performed from HLA-identical sibling donor with a median of 133 days from auto-SCT and results showed 4% TRM, 0% relapse, 19% and 74% of acute and chronic GVHD, respectively. Despite some differences in patient population and conditioning regimen for allo-SCT compared with our study, leading to different GVHD incidence, this analysis confirms the feasibility and safety of a tandem auto-allo approach in such a poor prognosis population and suggests a GVL effect, preventing relapse.
Similarly, our data may suggest the presence of an allogeneic GVL effect that adds to the cytoreductive impact of high-dose therapy: with a median follow-up of 46 months from allo-SCT, no relapse or progression occurred after 12 months (last relapse at day þ 236), with the presence of a plateau as shown in Figure 2 . However, caution is needed because clear evidence of a GVL effect is still lacking, due to limited numbers of events, as well as the uncontrolled nature of the study. Despite an observed reduction of relapse/progression risk among patients with chronic GVHD, this did not translate into better OS nor PFS because of higher NRM.
To better address the above mentioned issues, a prospective trial with well-defined risk criteria, histologies and homogeneous conditioning, as well as GVHD prophylaxis and tapering, would be very informative.
It is worth noting that a total of 150 patients treated at the two centers in the same period fulfilled the high-risk criteria but did Tandem auto-allo-SCT and NHL R Crocchiolo et al not receive tandem transplantation. This was mainly due to unfit patient's performance status or lack of HLA-identical donor.
We acknowledge that such a tandem transplantation could be performed only for those patients having a HLA-identical related or unrelated donor and such a donor is not available for all patients; 25, 26 we chose not to perform tandem auto-allo using alternative allogeneic donors due to the higher rate of nonengraftment and/or TRM. [27] [28] [29] In addition, use of unrelated donors was introduced some years later after HLA-identical siblings in our transplantation programs for lymphoma, explaining the unexpected ratio of 29:5 sibling:matched-unrelated donors. All these reasons may explain the rather low (18%, that is, 34 out of 150 þ 34 high-risk patients) rate of patients with high-risk features actually receiving tandem auto-allo in our cohort, compared with a theoretical 50% (that is, the probability to find a HLA-identical sibling or unrelated donor). 25, 26 In conclusion, despite several limitations the present results are encouraging because a limited toxicity and a potential prognosis improvement was observed in this series of consecutive patients treated with allo-SCT closely following high-dose chemotherapy and auto-SCT for high-risk NHL. The prompt start of the allogeneic donor search allowed to successfully identify a HLA-identical donor and to further proceed to tandem transplantation in this population.
